Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS
Corvus Pharmaceuticals — Technical Presentation (June 2017)
17 slides from Corvus Pharmaceuticals's technical presentation, Jun 5, 2017
Slide 1: Safety and clinical activity of A2aR antagonist CPI-444 in anti-PD1/PDL1 refractory RCC and NSCLC
Abstract #: 3004 Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI - 444, in anti - PD1/PDL1 treatment - refractory renal cell (RCC) and non - small cell lung cancer (NSCLC) patients Presenter: Lawrence Fong, M.D . Leader, Cancer Immunotherapy Program Co - Director , Park
Slide 2: Forward-looking statements
This presentation contains forward - looking statements, including statements related to the potential safety and efficacy of CPI - 444, both as a single agent and in combination with anti - PD - 1 and anti - PD - L1, and the Company’s ability to develop and advance product candidates int o and succ
Slide 3: Safety and clinical activity of A2aR antagonist, CPI-444, in refractory RCC and NSCLC patients
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI - 444 in anti - PD(L)1 treatment - refractory renal cell (RCC) and non - small cell lung cancer (NSCLC) patients Lawrence Fong, Patrick Forde , John Powderly II, Jonathan Goldman , John Nemunaitis , Jason Luke , Matthew He
Slide 4: Background
Background • Anti - PD - (L)1 antibodies are approved for treatment of RCC and NSCLC but a small proportion of patients benefit. • No approved agents overcome resistance to anti - PD - (L)1 with few reporting benefit in PD - 1 resistant/ refractory setting. • Converting tumors devoid of T cell infil
Slide 5: Adenosine Suppresses Immunity and is a Potential Mechanism of Resistance to PD-(L)1 Therapy
Adenosine Suppresses Immunity and is a Potential Mechanism of Resistance to PD - (L)1 Therapy CD73 expression in baseline tumor biopsies from the CPI - 444 phase 1 trial Adenosine in the tumor microenvironment Tumors can generate adenosine in response to anti - PD - (L)1 (Beavis et al, Can Immunol R
Slide 6: Phase 1/1b Clinical Study with Oral Drug CPI-444
Phase 1/1b Clinical Study with Oral Drug CPI - 444 Expansion cohorts: renal cell and non - small cell lung cancer CPI - 444 Monotherapy Dose Selection 100 mg BID or 200 mg QD, 14 or 28 days Cohort Expansion 100 mg BID 28 days CPI - 444 with atezolizumab (anti - PD - L1) Dose Selection 50 mg BID or 1
Slide 7: CPI-444 Blocks A2A Receptor Signaling
CPI - 444 Blocks A2A Receptor Signaling 50mg BID 100mg BID 200mg QD pCREB cAMP A2AR Adenosine CPI - 444 CD4+ T cell Ph I CPI - 444 Trial 0 5000 10000 15000 0 50 100 150 CPI-444 (ng/mL) A 2 A R P a t h w a y A c t i v i t y ( % R e l a t i v e t o B a s e l i n e ) Analysis of pCREB by flow cytometr
Slide 8: Patient Characteristics
Patient Characteristics Non - Small Cell Lung Cancer (N=45) Renal Cell Cancer (N=30) Prior anti - PD - (L)1 exposure Naïve Resistant/Refractory 8 (18%) 37 (82%) 8 (27%) 22 (73%) PD - L1 Negative* 54% 95% Median time since IO agent , months (range) 2.8 (0.6 – 24) 1.7 (1 – 71) Histology 28 (62%) Non s
Slide 9: Treatment-Related Adverse Events
Treatment - Related Adverse Events Grade > 3 AEs: • Single a gent: none • Combination CPI - 444 + atezolizumab • One patient with Gr 3 immune related hepatitis, pneumonitis, mucositis and dermatitis Adverse Events (Gr1/2) > 5% Frequency (n=75) Single Agent (%) Combination (%) Fatigue 11 15 Nausea 6
Slide 10: Disease Control in NSCLC
Phase 1/1b Trial with CPI - 444: Disease Control in NSCLC Partial responses can be seen in anti - PD - 1 progressors 10 (%) Change from Baseline Patients CPI - 444 Combination (CPI - 444+atezolizumab) Disease Control Duration Treatment (Months) Resistant/refractory to prior IO Naïve to prior IO PD -
Slide 11: Disease Control in Renal Cell Cancer
Phase 1/1b Trial with CPI - 444: Disease Control in Renal Cell Cancer Partial responses can be seen in an anti - PD - 1 progressing and naïve patients Resistant/refractory to prior IO Naïve to prior IO Treatment (Months) - - - - - - - - - - - - - - PD - L1 Positive / Negative + - CPI - 444 Combinati
Slide 12: Tumor Growth Kinetics in Stable RCC Patients
Tumor Growth Kinetics in “ Stable ” RCC Patients Days 12 12 -100 100 200 300 -80 -60 -40 -20 20 101001 SLD R e l a t i v e T a r g e t L e s i o n ( s ) S i z e Days -400 -200 200 400 -30 -20 -10 10 20 103101 SLD R e l a t i v e T a r g e t L e s i o n ( s ) S i z e Days -600 -400 -200 200 -30 -20 -
Slide 13: Tumor Regression in Nivolumab Refractory Renal Cancer
Tumor Regression in Nivolumab Refractory Renal Cancer Single Agent CPI - 444 Pre - treatment 3 months of treatment Five prior regimens including TKIs, mTOR inhibitor, and nivolumab Pre - treatment Post Dose (8w) 14% >70% H&E CD8 IHC Ph I CPI - 444 Trial 13 13 11
Slide 14: CPI-444 Induces CD8 T Cell Infiltration and Th1 Gene Expression in Tumor Tissues
CPI - 444 Induces CD8 T Cell Infiltration and Th1 Gene Expression in Tumor Tissues 14 14 Log Fold Change Gene Expression Post vs pre biopsies (N=14) Immune Gene Expression (paired biopsies) CD8 T Cell Change (IHC) NSCLC RCC Median 95% CI Pre - dose NSCLC Post - dose RCC Post - dose Pre - dose C D 8
Slide 15: CPI-444 Expands New T Cell Clones in Blood and Tumor
CPI - 444 Expands New T Cell Clones in Blood and Tumor Treatment induces expansion of identical T cell clones in blood and tumor Post treatment Pre - treatment Blood Tumor Biopsy 0.01 0.1 1 10 0.01 0.1 1 10 Screen Biopsy P o s t d o s e B i o p s y 15 15 • RCC patient with PR on single - agent CPI -
Slide 16: Phase 1/1b Trial with CPI-444: Summary
Phase 1/1b Trial with CPI - 444: Summary • CPI - 444 is well - tolerated as a monotherapy and in combination with atezolizumab • CPI - 444 has clinical activity alone and in combination with atezolizumab • Anti - tumor activity seen in: – Patients who have progressed on prior anti - PD - (L)1 – Pati
Slide 17: Acknowledgements
Acknowledgements • The patients and their families • Participating Centers: British Columbia Cancer Agency, Carolina BioOncology Institute, Cleveland Clinic, Columbia University Medical Center, Cross Cancer Institute, Emory University, Georgetown University, Indiana University, Johns Hopkins Univers
Corvus Pharmaceuticals — Technical Presentation (June 2017) on 6ix